Jubilant Pharmova Limited has convened its Forty-Eighth (48th) Annual General Meeting (AGM) for Wednesday, August 26, 2026, at 11:00 a.m. (IST), to be held through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The meeting will transact ordinary business including adoption of audited financial statements for FY 2025-26, declaration of a final dividend, and re-appointment of directors retiring by rotation.

AGM Key Dates and Voting Schedule

The following table summarises the important dates associated with the 48th AGM:

Members who wish to speak at the AGM may register as speakers by sending their queries from their registered email ID to investors@jubl.com from Monday, August 17, 2026, to Wednesday, August 19, 2026.

Agenda: Dividend and Director Re-appointments

The Board of Directors has recommended a final dividend of ₹5 per equity share of face value ₹1 each (500%) for the financial year ended March 31, 2026, aggregating to ₹796.41 million. The dividend is subject to member approval at the AGM and will be paid within 30 days of the meeting date to shareholders whose names appear in the Register of Members as on the record date of Friday, July 24, 2026.

The AGM will also consider the re-appointment of two directors retiring by rotation:

• Mr. Hari Shanker Bhartia (DIN: 00010499), Co-Chairman, aged 69 years, a Chemical Engineering graduate from IIT Delhi. He has been on the Board since November 1, 1983, and holds 3,60,885 shares of the Company. During FY 2025-26, sitting fees of ₹0.6 million were paid to him, and commission of ₹1.5 million for the said financial year shall be paid upon approval of Financial Statements at the ensuing AGM.

• Mr. Arjun Shanker Bhartia (DIN: 03019690), Joint Managing Director, aged 39 years, with approximately 18 years of industry experience. He has been on the Board since May 23, 2017, and has served as Joint Managing Director since June 1, 2023. He does not hold any shares of the Company. Mr. Arjun Shanker Bhartia was paid remuneration of ₹75.00 million in FY 2025-26.

Both directors attended all six (6) Board meetings held during FY 2025-26.

FY 2025-26 Financial Performance

The company delivered broad-based revenue growth across all business segments in FY 2025-26. The following table presents the consolidated financial highlights:

Revenue grew 14% year-over-year to ₹82,796 Million, driven by strong performance across all business units, particularly CDMO Sterile Injectables. Normalised PAT increased 7% to ₹4,424 Million due to improved operating performance and reduction in finance cost. Profit Before Tax declined to ₹6,141 Million from ₹9,806 Million in FY 2025, primarily due to an exceptional expense of ₹592 Million in FY 2026 compared to exceptional income of ₹3,595 Million in FY 2025.

Segment-Wise Revenue Performance

The table below presents segment revenue for FY 2025-26 versus FY 2024-25:

The CDMO Sterile Injectables segment was the standout performer, with revenue rising 38% year-over-year to ₹17,548 Million. The Spokane facility recorded a robust 48% revenue growth, driven by commercial technology transfer revenues from Line 3. Ruby-Fill® installations grew 35% in the Radiopharmaceuticals segment. The Generics segment reported EBITDA growth of 250% to ₹827 Million.

Vision 2030 Progress

The company is tracking against its Vision 2030 targets of doubling revenues from FY 2024 to FY 2030, reaching 23%–25% EBITDA margins, zero net debt, and high-teens Return on Capital Employed (ROCE).

*EBIT before exceptional items / Average ((Equity + Gross Debt) less (CWIP adjusted for grant))

The Net Debt/EBITDA ratio moved from 1.1x as on March 2025 to 1.3x as on March 2026, reflecting deliberate growth capital expenditure commitments.

TDS on Dividend and Shareholder Information

Pursuant to the Finance Act, 2020, dividend income is taxable in the hands of shareholders with effect from April 1, 2020. The Company will deduct tax at source at prescribed rates. For resident individual shareholders, no TDS will be deducted if total dividend paid during FY 2026-27 does not exceed ₹10,000. Shareholders are requested to submit relevant tax documents on or before August 14, 2026, to enable the Company to determine the appropriate TDS/withholding tax rate. The dividend, if declared, will be taxable in the hands of shareholders in FY 2026-27 (Assessment Year 2027-28).

The AGM notice, Annual Report for FY 2025-26, and related documents are available on the Company's website at www.jubilantpharmova.com . Shareholders may contact the Registrar and Transfer Agent, Alankit Assignments Limited, at rta@alankit.com or +91-11-4254 1234 for any share-related queries.

Jubilant Pharmova Limited has notified shareholders of an August 14, 2026, deadline to submit tax documentation for its proposed final dividend of ₹5 per equity share. The communication, issued on August 1, 2026, outlines withholding tax rates and exemption procedures under the Income-tax Act, 2025, ensuring investors can optimize their tax liability before the record date of July 24, 2026. This procedural update follows the Board’s recommendation of the dividend on May 22, 2026, subject to approval at the Annual General Meeting (AGM) scheduled for August 26, 2026.

Dividend Taxation and Submission Deadlines

The company will deduct tax at source (TDS) based on shareholder category and residential status unless valid exemptions are claimed. Shareholders must submit requisite forms and declarations to Alankit Assignments Limited or their Depository Participants by August 14, 2026. Documents received after this date will not be considered for lower or nil tax deduction.

For resident individuals, no tax will be deducted if the total dividend received in FY 2026-27 does not exceed ₹10,000. However, if PAN is not registered or linked with Aadhaar, TDS will be applied at a higher rate of 20% under Section 397(2) of the Income-tax Act, 2025, regardless of the dividend amount. Non-resident shareholders seeking treaty benefits must provide a Tax Residency Certificate, e-filed Form 41, and a self-declaration confirming no permanent establishment in India.

AGM and Financial Context

The dividend recommendation is part of the business transacted at the 48th AGM on August 26, 2026. The meeting will also adopt audited financial statements for FY 2025-26, where Jubilant Pharmova reported revenue from operations of ₹82,796 million, a 14% increase year-on-year. Normalised Profit After Tax (PAT) rose 7% to ₹4,424 million. The proposed dividend aggregates to ₹796.41 million.

Shareholders holding shares in dematerialized mode are advised to update KYC details, including PAN and bank accounts, with their Depository Participants. Those holding physical shares must coordinate directly with the company or its Registrar and Transfer Agent. The company reserves the right to verify PAN status independently and apply higher withholding rates if discrepancies are found.

Key Dates for Shareholders

Investors are urged to consult tax advisors as the communication does not constitute exhaustive tax advice. The company will issue TDS certificates via email post-filing of returns, allowing shareholders to download Form 168 from the Income Tax Department’s portal.